載入中
NASDAQHealthcareBiotechnology
最新資料
US$21.555
−US$0.02 · -0.09%
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
一般交易時段
US$21.555
−US$0.02 · -0.09%
盤中時間採用ET。市場資料可能有所延遲。
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
日內區間
目前US$21.555
52週區間
目前US$21.555
盤中時間採用ET。市場資料可能有所延遲。
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
日內區間
目前US$21.555
52週區間
目前US$21.555
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2250.3萬 USD | 4556.3萬 USD | 1409萬 USD | 1.03億 USD | — |
| 銷貨成本 | 5.9萬 USD | — | — | — | — |
| 毛利 | 2244.4萬 USD | 4556.3萬 USD | 1409萬 USD | 1.03億 USD | — |
| 研究與開發 | 1.42億 USD | 1.51億 USD | 1.59億 USD | 8674.4萬 USD | 2897.4萬 USD |
| 銷售、一般及管理費用 | 1.06億 USD | 7044.6萬 USD | 3763.3萬 USD | 1950.7萬 USD | 567.7萬 USD |
| 營業費用 | 2.48億 USD | 2.22億 USD | 1.97億 USD | 1.06億 USD | 3497.7萬 USD |
| 利息收入 | 2759.2萬 USD | 1688.1萬 USD | 1022.01萬 USD | — | — |
| 利息支出 | — | — | 679.91萬 USD | 28.7萬 USD | 41.1萬 USD |
| 折舊和攤銷 | 22萬 USD | 11.3萬 USD | 4.9萬 USD | 9000 USD | 5000 USD |
| 營業利益 | −2.26億 USD | −1.76億 USD | −1.83億 USD | −355.7萬 USD | −3497.7萬 USD |
| 淨利 | −2.04億 USD | −2.42億 USD | −1.77億 USD | −2263.4萬 USD | −4178.5萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$51.33
上漲空間 138.14%報告持有此股票曝險的交易所交易基金。
Capital Group U.S. Small and Mid Cap ETFCGMM1611.82萬0.46%35.39億 USD0.51%US$31.52-0.91%
iShares Biotechnology ETFIBB1295萬0.12%108.2億 USD0.44%US$204.53-0.95%
Vanguard Health Care ETFVHT497.72萬0.02%220億 USD0.09%US$319.6+0.18%
ALPS Medical Breakthroughs ETFSBIO327.61萬1.71%1.91億 USD0.50%US$54.305-1.34%
Fidelity Fundamental Small-Mid Cap ETFFFSM130.63萬0.08%14.4億 USD0.43%US$34.065-0.19%
iShares ESG Aware MSCI USA Small-Cap ETFESML109.22萬0.04%27.28億 USD0.17%US$52.575-0.31%
Fidelity Nasdaq Composite Index ETFONEQ73.64萬0.01%109.4億 USD0.21%US$107.4-0.38%
Fidelity MSCI Health Care Index ETFFHLC69.16萬0.02%35.4億 USD0.08%US$82.585+0.16%Capital Group U.S. Small and Mid Cap ETFCGMMiShares Biotechnology ETFIBBVanguard Health Care ETFVHTALPS Medical Breakthroughs ETFSBIOFidelity Fundamental Small-Mid Cap ETFFFSMiShares ESG Aware MSCI USA Small-Cap ETFESMLFidelity Nasdaq Composite Index ETFONEQFidelity MSCI Health Care Index ETFFHLCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
